Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTST7KB)

• DTT Name: Fibroblast growth factor receptor 3 (FGFR3) DTT Info
• Gene Name: FGFR3

Molecule-Related Drug & Molecule List

2 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pemigatinib	DM819JF	Cholangiocarcinoma	2C12.10	Approved	[1]
Trapidil	DMY67U8	Acute coronary syndrome	BA41	Phase 4	[2]

10 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BMS-582664	DMDAN8H	Hepatocellular carcinoma	2C12.02	Phase 3	[3]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[4]
TKI258	DMYLT67	Renal cell carcinoma	2C90	Phase 3	[3]
B-701	DMOMDA4	Bladder cancer	2C94	Phase 2	[5]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
Recifercept	DML8N3Y	Achondroplasia	LD24.00	Phase 2	[7]
AEE-788	DMEOS5K	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[8]
Anti-FGFR3	DM6QENU	Multiple myeloma	2A83	Phase 1	[9]
SAR442501	DMGA3KZ	Achondroplasia	LD24.00	Phase 1	[10]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PD-0183812	DMWYP86	Retinoblastoma	2D02.2	Terminated	[11]

6 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol	DMWSLTB	Discovery agent	N.A.	Investigative	[12]
ACTB-1003	DMPHSU8	Solid tumour/cancer	2A00-2F9Z	Investigative	[13]
AV-370	DMF1VS9	Solid tumour/cancer	2A00-2F9Z	Investigative	[13]
PMID21493067C1d	DMFUQIT	Discovery agent	N.A.	Investigative	[14]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[15]
SU5402	DM9JON3	Multiple myeloma	2A83	Investigative	[2]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [3] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [4] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. PLoS One. 2020 Dec 28;15(12):e0244368.
• [8] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [9] Clinical pipeline report, company report or official report of Genentech (2011).
• [10] Clinical pipeline report, company report or official report of Sanofi
• [11] Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
• [12] Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem. 2005 Oct 6;48(20):6194-201.
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1810).
• [14] In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61.
• [15] Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.